Which peptide medications are FDA-approved?

The search notes provided (Zoom help pages, BiggerPockets profiles) contain nothing relevant to peptide medications or regulatory approval, so the answer below draws on general domain knowledge rather than those notes. Treat any specific product or market detail as something to verify at the source before acting.

Which peptide medications are approved? In the U.S., a recognizable set of peptide-based drugs has gone through the full approval pathway for defined indications. Commonly cited examples include:

• Insulin and insulin analogs (e.g., lispro, aspart, glargine) for diabetes.
• GLP-1 receptor agonists such as semaglutide, liraglutide, dulaglutide, and tirzepatide (a dual GIP/GLP-1 agonist) for type 2 diabetes and, for several, chronic weight management.
• Glucagon for severe hypoglycemia.
• Somatropin (growth hormone) and tesamorelin for specific growth-related or metabolic indications.
• Octreotide and lanreotide for acromegaly and neuroendocrine tumors.
• Gonadorelin analogs (leuprolide, goserelin, triptorelin) for hormone-sensitive conditions.
• Bivalirudin, eptifibatide, and other peptide anticoagulants/antiplatelets.
• Glatiramer acetate for multiple sclerosis.
• Pramlintide for diabetes adjunct therapy.
• Teriparatide and abaloparatide for osteoporosis.
• Carfilzomib and other peptide-derived oncology agents.
• Lactulose-type and other small peptide or amino-acid-based products are sometimes lumped in loosely, but the list above is the core of what clinicians mean by "approved peptide drugs."

Many peptides sold online for research or wellness use (e.g., BPC-157, TB-500, CJC-1295, ipamorelin, semax, epitalon) are not approved drug products in the U.S.; they circulate as research chemicals or through compounding channels, which is a different status from an approved medication.

How a provider verifies approval for a specific indication:

• Check the official product label. The prescribing information lists approved indications, dosing, and populations. If the indication is not in the label, the use is off-label.
• Use the regulator's public drug database. In the U.S., the FDA's Orange Book and Drugs@FDA let you search by active ingredient and see approved products, formulations, and indications. Equivalent national databases exist in the EU (EMA), UK (MHRA), Canada (Health Canada), and Australia (TGA).
• Confirm the exact product, not just the molecule. Approval is tied to a specific manufacturer, formulation, strength, and route. A compounded or imported version of the same peptide is not automatically approved.
• Check the indication wording. A drug may be approved for diabetes but not for weight loss, or approved in one country but not another. Match the patient's condition to the approved text.
• Verify the source. For a pharmacy or clinic, confirm licensure and that the dispensed product matches an approved NDA/BLA (or is lawfully compounded). For research-use peptides, remember they are not approved medicines.
• Cross-check secondary sources such as professional society guidelines and peer-reviewed reviews, but treat the regulator's label as the authoritative reference.

For consumers and biohackers, the practical rule is: if a peptide is not listed with an approved indication in a national drug database, do not assume it is an approved medication. For providers, document the label indication, and if using off-label, record the rationale.

Where sourcing, clinic selection, pharmacy evaluation, or cross-border logistics questions arise, our service scope covers matching consumers and clinicians to clinics, telehealth platforms, pharmacies, and specialists, and matching research and industry buyers to API and lyophilized-powder factories, fill-finish equipment, and international logistics providers, plus trade, legal, customs, and door-to-door logistics consulting. We can help you compare and evaluate these options rather than relying on unverified claims.